As one of the most prevalent diseases in younger children and a top ranking reason for office and hospital visits, bronchiolitis is an entity that pediatricians and primary care physicians must be able to understand, identify, and treat, requiring knowledge of the most up to date evidence. This activity will outline the new AAP recommendations for bronchiolitis that were recently established in 2014. Dr. Sidhpura from Mattel Children’s Hospital at UCLA will begin with a brief pathophysiology of bronchiolitis and discuss its clinical course and complications. She will explore and discuss the evidence-based studies used by the AAP to draw up the current treatment recommendations. Finally, she will outline the recommendations for administration of palivizumab, the monoclonal antibody aimed at preventing RSV in select groups.